ClinicalTrials.gg
TerminatedNCT00782041Updated Sep 15, 2009

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

A Phase 2 interventional study of Oxaliplatin and 5-FluoroUracil in Uterine Neoplasms, sponsored by Sanofi. Terminated at 1 site in Thailand. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-15.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
protocol violation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Primary:

  • To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline.

Secondary:

  • To assess the safety and tolerability of oxaliplatin
  • To assess time to progression and overall survival.
02

Conditions studied

  • Uterine Neoplasms

Browse trials for

03

In context

Uterine Neoplasms

249 studies on the registry are indexed under Uterine Neoplasms; 60 are open to participants now.

This study's enrollment of 11 is below the median of 48 across 174 interventional studies indexed under Uterine Neoplasms.

Browse Uterine Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Locally advanced/ squamous or adenocarcinoma of the cervix
  • Prior therapy with cisplatin allowed
  • treatment may have been surgery,radiotherapy or chemotherapy either as a single agent or multi-modality therapy
  • Must have
  • Proven Carcinoma of the cervix
  • PS ≤2
  • No other serious concomitant illness
  • Fully recovered from any prior therapy
  • Lab: >1500 mm³, > 100000 mm³, Creatinine ≤ 1.5 x Normal value, ≤ 1.5 x Normal value, (ALT) ≤ 2.5 x Normal value

Exclusion criteria

Exclusion Criteria:

  • Known allergy to one of the study drugs
  • Peripheral neuropathy > grade2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    1

    Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.

    Drug: Oxaliplatin · Drug: 5-FluoroUracil · Drug: Folinic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Response rate

    Time frame: Throughout the study period

Secondary outcomes

  1. Progression-free survival

    Time frame: Throughout the study period

  2. Overall survival

    Time frame: Throughout the study period

  3. Adverse events

    Time frame: Throughout the study period

07

Study locations

1 site
  • Sanofi aventis administrative office
    Bangkok, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a primary completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2008
First posted
Oct 29, 2008
Start
Jan 2003
Primary completionActual
Aug 2003
Last update
Sep 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00782041
Lead sponsor
Sanofi
First posted
Oct 29, 2008
Start date
Jan 2003
Primary completion
Aug 2003
Last update
Sep 15, 2009

Study contacts

Paibulsirijit Sompob, MD
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Fluorouracil · Leucovorin

Start the discussion